Acute lymphoblastic leukemia other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 16: Line 16:


==RT-PCR and FISH==
==RT-PCR and FISH==
*In addition, for B-cell disease, the malignant cells should be analyzed using RT-PCR and FISH for evidence of the bcr-abl fusion gene. This last point is of utmost importance, as timely diagnosis of Ph1 ALL will significantly change the therapeutic approach.
*In addition, for B-cell disease, the malignant cells should be analyzed using RT-PCR and FISH for evidence of the bcr-abl fusion gene. This last point is of utmost importance, as timely diagnosis of Ph1 ALL will significantly change the therapeutic approach.<ref name=ALL>{{cite web | title = National Cancer Institute| url =http://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq#link/_44_toc }}</ref>


==References==
==References==

Revision as of 20:02, 25 August 2015

Acute lymphoblastic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Acute lymphoblastic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Bone X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute lymphoblastic leukemia other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute lymphoblastic leukemia other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute lymphoblastic leukemia other diagnostic studies

CDC on Acute lymphoblastic leukemia other diagnostic studies

Acute lymphoblastic leukemia other diagnostic studies in the news

Blogs on Acute lymphoblastic leukemia other diagnostic studies

Directions to Hospitals Treating Acute lymphoblastic leukemia

Risk calculators and risk factors for Acute lymphoblastic leukemia other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Cytogenetics

Biopsy

  • A biopsy is the only sure way to know whether leukemia cells are in the bone marrow. Before the sample is taken, local anesthesia is used to numb the area. This helps reduce the pain. Bone marrow from your hipbone or another large bone is taken as biopsy.[1]
  • A bone marrow biopsy and aspirate are routinely performed even in T-cell ALL to determine the extent of marrow involvement. Malignant cells should be sent for conventional cytogenetic studies, as detection of the Ph1 t(9;22), myc gene rearrangements (in Burkitt leukemia), and MLL gene rearrangements add important prognostic information[2]

Flow cytometry

  • Flow cytometry should be performed to characterize expression of lineage-defining antigens and allow determination of the specific ALL subtype.[2]

RT-PCR and FISH

  • In addition, for B-cell disease, the malignant cells should be analyzed using RT-PCR and FISH for evidence of the bcr-abl fusion gene. This last point is of utmost importance, as timely diagnosis of Ph1 ALL will significantly change the therapeutic approach.[2]

References

  1. Harrison's Principles of Internal Medicine, 16th EditioN, Chapter 97. Malignancies of Lymphoid Cells. Clinical Features, Treatment, and Prognosis of Specific Lymphoid Malignancies.
  2. 2.0 2.1 2.2 "National Cancer Institute".

Template:WH Template:WS